Published November 30, 2021 | Version v1
Journal article Open

Prevalence of mupirocin resistant (mupA) gene in S. aureus isolates from two tertiary care hospitals of Punjab

Creators

  • 1. Institute of Molecular Biology and Biotechnology University of Lahore, Pakistan
  • 2. Department of Bioscience, Comsats University Islamabad, Pakistan
  • 3. Department of Medical Lab Technology, Faculty of Rehabilitation and Allied Health Sciences, Riphah International University Islamabad, QIE Campus Lahore, Pakistan
  • 4. Chugtai Lab Jail Road Lahore, Pakistan

Description

Introduction: Mupirocin is a topical ointment and de-colonizing agent, used to reduce the burden of Staphylococcus aureus from nasal nares. Unjudiciary use of mupirocin has resulted in the emergence of resistance mediated by a gene mupA found to be associated with high-level mupirocin (HLMup R) resistance. The objectives of this study were to find out the prevalence of MRSA/MSSA, mupA gene, and antimicrobial resistance among burn patients and outdoor patients.

Material and Methods: A total of 238 non-repetitive specimens were collected from nasal nares and burn wounds of patients in two tertiary care hospitals. S. aureus was isolated by conventional biochemical and molecular methods. Prevalence of resistance gene and antimicrobial susceptibility were identified by PCR and Kirby Bauer disk diffusion method respectively.

Results: The prevalence of MRSA was 13% (32/238) and MSS 29% (70/238). We screened 102 isolates for the mupA gene and found 21 MRSA and 12 MSSA with a total of 33 isolates carrying this gene and the p-value was 0.0001. Most strains were found to be MDR.

Discussion and Conclusion: MRSA strains are prevailing in hospital environments whereas mupA gene carriage rate shows that antimicrobial use of mupirocin to decolonize bacteria needs to be minimized. Antimicrobial stewardship and closed surveillance may be regulated.

Files

Prevalence of mupirocin resistant (mupA) gene in S. aureus isolates from two tertiary care hospitals of Punjab.pdf

Files (256.6 kB)

Additional details

References

  • Iqbal, M. S., Saleem, Y., Ansari, F., Qamar, M. U., Mazhar, S., Hassan, A., ... & Syed, Q. (2018). Staphylococcus aureus carrying lukS/F Panton-Valentine Leukocidin (PVL) toxin genes in hospitals of Lahore city. The Journal of Infection in Developing Countries, 12(09), 720-725.
  • Ringberg H, Petersson AC, Walder M, Johansson PJH. (2006) The throat: an important site for MRSA colonization. Scand J Infect Dis 38:888–893.
  • Foster, T. J. (2005). Immune evasion by staphylococci. Nature reviews microbiology, 3(12), 948-958.
  • Lobdell, K. W., Stamou, S., & Sanchez, J. A. (2012). Hospital-acquired infections. Surgical Clinics, 92(1), 65-77.
  • Shittu, A. O., Kaba, M., Abdulgader, S. M., Ajao, Y. O., Abiola, M. O., & Olatimehin, A. O. (2018). Mupirocin-resistant Staphylococcus aureus in Africa: a systematic review and meta-analysis. Antimicrobial Resistance & Infection Control, 7(1), 1-16.
  • Alicia, I. H., Edwards, J. R., Patel, J., Horan Teresa, C., & Sievert Dawn, M. (2008). NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infection Control and Hospital Epidemiology, 29, 996-1011.
  • Lowy, F. D. (1998). Staphylococcus aureus infections. N. Engl. J. Med.
  • Litzler, P. Y., Benard, L., Barbier-Frebourg, N., Vilain, S., Jouenne, T., Beucher, E., ... & Bessou, J. P. (2007). Biofilm formation on pyrolytic carbon heart valves: influence of surface free energy, roughness, and bacterial species. The Journal of thoracic and cardiovascular surgery, 134(4), 1025-1032.
  • Zhang K., McClure J.-A., Elsayed S., Louie T., Conly J. M. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. Journal of Clinical Microbiology. 2005;43(10):5026–5033. doi: 10.1128/jcm.43.10.5026-5033.2005
  • Anthony, R. M., A. M. Connor, E. G. Power, and G. L. French. Use of the polymerase chain reaction for rapid detection of high-level mupirocin resistance in staphylococci. Eur. J. Clin. Microbiol. Infect. Dis1999. 18:30-34.
  • Simpson I N., Gisby J, Hemingway C P., Durodie j, and Macpherson I. Evaluation of Mupirocin E-test for Determination of Isolate Susceptibility: Comparison with Standard Agar Dilution Techniques. Journal of Clinical Microbiology, 1995. p. 2254–2259.
  • Khoshnood, S., Heidary, M., Asadi, A., Soleimani, S., Motahar, M., Savari, M., ... & Abdi, M. (2019). A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against Staphylococcus aureus. Biomedicine & Pharmacotherapy, 109, 1809-1818.
  • Krishnan P U, Miles K, Shetty N. Detection of methicillin and mupirocin resistance in Staphylococcus aureus isolates using conventional and molecular methods: a descriptive study from a burns unit with high prevalence of MRSA J Clin Pathol 2002;55:745–748.
  • Andrew E. Simor, Tammy L. Stuart, Lisa Louie, Christine Watt,1 Marianne Ofner-Agostini, Denise Gravel, Michael Mulvey, Mark Loeb, Allison McGeer, Elizabeth Bryce, Anne Matlow, and the Canadian Nosocomial Infection Surveillance Program. Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus Strains in Canadian HospitalsAntimicrob Agents Chemother2007, Vol. 51, No. 11 p. 3880–3886.
  • McNeil JC, Hulten KG, Kaplan SL, Mason EO. 2011. Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children Antimicrob Agents Chemother 55:2431–2433.
  • Antonov NK, Garzon MC, Morel KD et al. High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population. Antimicrob Agents Chemother 2015; 59:3350–6.
  • Ng, S. M. S., Ching, H. S. V., Xu, G., Ng, F. M., Ong, E. H., Lau, Q. Y., ... & Chia, C. B. (2017). Screening for a potent antibacterial peptide to treat mupirocin-resistant MRSA skin infections. International Journal of Peptide Research and Therapeutics, 23(4), 481-491.
  • Park SY, Kim SM, Park SD. The prevalence, genotype and antimicrobial susceptibility of high-and low-level mupirocin resistant methicillin-resistant Staphylococcus aureus. Annals of dermatology. 2012 Feb 1;24(1):32-8.
  • Desroches, M., Potier, J., Laurent, F., Bourrel, A.S., Doucet-Populaire, F., & Decousser, J.W. (2013). Prevalence of mupirocin resistance among invasive coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus (MRSA) in France: emergence of a mupirocin-resistant MRSA clone harbouring mupA. The Journal of antimicrobial chemotherapy, 68 8, 1714-7.
  • Eltringham I. Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 1997; 35: 1-8
  • Hiramatsu, K., Ito, T., Tsubakishita, S., Sasaki, T., Takeuchi, F., Morimoto, Y., ... & Baba, T. (2013). Genomic basis for methicillin resistance in Staphylococcus aureus. Infection & chemotherapy, 45(2), 117.
  • Andersson, H., Lindholm, C., & Fossum, B. (2011). MRSA–global threat and personal disaster: patients' experiences. International nursing review, 58(1), 47-53.
  • Khan, T. M., Kok, Y. L., Bukhsh, A., Lee, L. H., Chan, K. G., & Goh, B. H. (2018). Incidence of methicillin-resistant Staphylococcus aureus (MRSA) in burn intensive care unit: a systematic review. Germs, 8(3), 113.

This site uses cookies. Find out more on how we use cookies